

MOL #79616

**Cysteine residues in the TM9-TM11 region of the human equilibrative nucleoside transporter subtype 1 play an important role in inhibitor binding and translocation function.**

Jamie S. Park and James R. Hammond

Department of Physiology and Pharmacology

Schulich School of Medicine and Dentistry

Western University

London, Canada

MOL #79616

**Running Title:** Role of cysteines in hENT1 function

**Address correspondence to:**

Dr. James R Hammond, Dept. of Physiology and Pharmacology, M266 Medical Sciences Building,  
Western University, London, Ontario, N6A 5C1, Canada.

E-mail: [jhammo@uwo.ca](mailto:jhammo@uwo.ca); Tel: 519-661-3780; Fax: 519-661-3827

Number of text pages: 31

Number of Tables: 3

Number of Figures: 8

Number of References: 31

Abstract: 294 Introduction: 1144

Discussion: 1536

ABBREVIATIONS: ENT, equilibrative nucleoside transporter; hENT, human ENT; mENT1, mouse ENT1; WT, wild-type; MMTS, methyl methanethiosulfonate; MTSES, sodium (2-sulfonatoethyl)-methanethiosulfonate; MTSET, [2-(trimethylammonium)ethyl] methane-thiosulfonate; NBMPR, nitrobenzylmercaptapurine riboside; NBTGR, nitrobenzylthioguanosine riboside; NEM, N-ethylmaleimide; NMG, N-methylglucamine; TBS, Tris Buffered Saline; PBS, phosphate-buffered saline; PK15-NTD, nucleoside transport deficient pig kidney epithelial cells derived from the PK15 cell line; TM, transmembrane; pCMBS, p-chloromercuribenzenesulfonate; 2-Br, 2-Bromohexadecanoic acid; FTH-SAENTA, 5'-S-[2-(1-[(fluorescein-5-yl)thioureido]-hexanamido)ethyl]-6-N-(4-nitrobenzyl)-5'-thioadenosine

MOL #79616

## ABSTRACT

Inhibitor and substrate interactions with equilibrative nucleoside transporter 1 (ENT1; SLC29A1) are known to be affected by cysteine-modifying reagents. A previous study from our laboratory established Cys222 in TM6 as the residue responsible for MMTS (membrane-permeable sulfhydryl modifier)-mediated enhancement of the binding of the ENT1 inhibitor nitrobenzylthioinosine (NBMPR) in intact cells. However, the capacity of charged sulfhydryl reagents to inhibit the binding of NBMPR in broken cell preparations (allowing cytoplasmic access) was not affected by mutation of any of the cysteines (Cys87, 193,213, 222) in the N-terminal half of the protein. We thus hypothesized that the inhibitory effects of the modifiers were due to the one or more of the six cysteine residues in the C-terminal half of ENT1, particularly one or both of those in the fifth intracellular loop (Cys414 and Cys416). Each of the cysteines were mutated to serine or alanine and expressed in nucleoside transport deficient PK15 cells and probed with a series of methanethiosulfonate sulfhydryl modifying reagents. Transporter function was assessed by the site-specific binding of [<sup>3</sup>H]NBMPR and the cellular uptake of [<sup>3</sup>H]2-chloroadenosine. These studies established that Cys378 is an extracellular-located residue modified by MTSET to inhibit the binding of NBMPR to intact cells. Mutation of Cys414 led to an enhancement of the ability of MTSET to inhibit NBMPR binding and this enhancement was eliminated by the co-mutation of Cys378, indicating that disruption of the fifth intracellular loop modifies the conformation of TM10 and its extracellular loop. Mutation of Cys416 led to the loss of the ability of the charged sulfhydryl reagents to inhibit NBMPR binding in isolated membranes, and also led to the loss of transport function. This finding further supports an allosteric interaction between the fifth intracellular loop and the extracellular NBMPR binding domain, and implicates this region in the translocation function of hENT1.

MOL #79616

## INTRODUCTION

Human equilibrative nucleoside transporter 1 (hENT1) is a ubiquitous integral membrane protein that mediates the movement of hydrophilic nucleosides across cell membranes. It functions by carrier-mediated facilitative diffusion and is sensitive to inhibition by nanomolar concentrations of 4-nitrobenzylmercaptapurine riboside (NBMPR) (Sundaram et al., 2001a). Inhibition of hENT1 has been shown to enhance the cardioprotective and neuroprotective actions of adenosine (Cunha, 2001; King et al., 2006; Loffler et al., 2007). hENT1 is also utilized by anti-cancer nucleoside analogues for access into tumor cells and is thus an important chemotherapeutic target (Pastor-Anglada et al., 2005; Zhang et al., 2007).

Based on antibody analyses and topology modeling, the conventional model of hENT1 combines a cytoplasmic N-terminus and extracellular C-terminus with 11 transmembrane (TM) domains (Sundaram et al., 2001a; Sundaram et al., 2001b; Sundaram et al., 1998) (Fig. 1). Studies using ENT subtype chimeras and site-directed mutagenesis have identified the TM 3-6 region to be critical to transporter function and contributes to interactions with hENT1 inhibitors and substrates. In particular, Gly154 and Ser160 in TM 4 impact on NBMPR sensitivity while Gly179 and Gly184 in TM 5 are indicated in the affinity of nucleosides and proper membrane targeting, respectively (Endres and Unadkat, 2005; SenGupta et al., 2002; SenGupta and Unadkat, 2004).

At present, a complete structural model of hENT1 is lacking due to the difficulty in isolating hENT1 in its native membrane configuration. Alternative techniques for advancing knowledge of ENT1 structure-function have thus been employed, including cysteine-mutagenesis in conjunction with cysteine-selective sulfhydryl modifying reagents (Park et al., 2011; Riegelhaupt et al., 2010; Valdes et al., 2004; Yao et al., 2011). The importance of cysteines in hENT1 function has been shown in multiple studies using N-

MOL #79616

ethylmaleimide (NEM) and p-chloromercuriphenylsulfonic acid (pCMBS) as sulfhydryl modifiers. In mouse Ehrlich ascites tumor cells and human erythrocytes (Vyas et al., 2002), it was found that inhibitor binding to ENT1 in intact cells was sensitive to NEM, which is membrane-permeable, while only the broken cell preparations were sensitive to pCMBS, a negatively charged membrane-impermeable reagent; these data are suggestive of intracellular cysteines being involved in ENT1-ligand interactions. In intact HeLa cells, both pCMBS and NEM were shown to alter the  $B_{max}$  and  $K_d$  of NBMPR binding (Dahlig-Harley et al., 1981), although NEM was much more potent in that regard suggesting a relatively hydrophobic environment of the target cysteine. We have recently described modification of hENT1 ligand binding and transport function using a series of methanethiosulfonate (MTS) reagents (Park et al., 2011). The membrane permeable methyl methanethiosulfonate (MMTS) enhanced [ $^3$ H]NBMPR binding in a pH-dependent manner and decreased [ $^3$ H]2-chloroadenosine uptake, while the positively charged, membrane-impermeable [2-(trimethylammonium) ethyl] methane-thiosulfonate (MTSET) inhibited [ $^3$ H]NBMPR binding and enhanced [ $^3$ H]2-chloroadenosine uptake by hENT1. The negatively charged, membrane-impermeable (2-sulfonatoethyl) methanethiosulfonate (MTSES), like pCMBS (also negatively charged), was found to inhibit NBMPR binding only in broken cell preparations, again implicating an intracellular cysteine. In that study, Cys222 was identified as the critical residue for MMTS enhancement of NBMPR binding, but the extracellular cysteine responsible for MTSET sensitivity was not identified. Likewise, the location of the MTSES-sensitive intracellular cysteine remained undefined.

Cys414 and Cys416 are the only cysteine residues predicted to be located in an intracellular aqueous accessible region (loop between TM10 and 11). Thus we hypothesized that it was one of these two cysteines that were the target for the charged MTS reagent effects on ENT1 function. Further evidence for a role of the C-terminal end of ENT1 being involved in ligand binding comes from studies on a truncated splice variant of mENT1 missing the last three transmembrane domains (mENT1Delta11). This variant lost the ability to be photolabeled with NBMPR, and was also found to be less sensitive to NEM, relative to its full length counterpart (Robillard et al., 2008). Although this suggested the region was not essential

MOL #79616

for transporter function, it did imply that NEM sensitivity of NBMPR binding may be due to modification of cysteines encompassed by TMs 9-11. In addition, Visser and colleagues have shown that Leu442 in TM11 of hENT1 (one helix turn above Cys439; see Fig. 1) is involved in transporter permeant selectivity, and may contribute to the interaction of the inhibitor dipyridamole with hENT1 (Visser et al., 2005; Visser et al., 2007).

In the present work, we have examined the roles of the six cysteines found within the C-terminal half of hENT1 with regard to transporter function and the binding of NBMPR. With the use of site-directed mutagenesis, combined with differential sensitivity to a series of MTS reagents, we have describe residues Cys378, Cys414, and Cys416 as having important but divergent roles in hENT1 function and ligand binding.

MOL #79616

## MATERIALS AND METHODS

### *Materials:*

[<sup>3</sup>H]NBMMPR (5.5-20.1 Ci/mmol), [<sup>3</sup>H]2-chloroadenosine (9.1 Ci/mmol), and [<sup>3</sup>H]water (1 mCi/g) were obtained from Moravek Biochemicals (Brea, California). MMTS, MTSET, and MTSES were acquired from Toronto Research Chemicals (Toronto, Ontario, Canada). Culture-grade phosphate-buffered saline (PBS), Modified Eagle's Medium (MEM), G418 (Geneticin), penicillin/streptomycin, trypsin/EDTA, sodium pyruvate, nonessential amino acids, Lipofectamine 2000, and Lipofectamine LTX were purchased from Invitrogen (Burlington, ON, Canada). Oligonucleotide primers were obtained from Sigma-Genosys (Oakville, ON, Canada). NBMMPR, 2-chloroadenosine, dipyrindamole, and S-(4-nitrobenzyl)-6-thioguanosine (NBTGR), and p3×FLAG-CMV10 vector were purchased from Sigma-Aldrich (Oakville, ON, Canada.). 2-Bromohexadecanoic acid (2-Br) was purchased from Sigma Aldrich. The primary mouse monoclonal anti-FLAG antibody and secondary goat anti-mouse antibody were purchased from Sigma (Oakville, ON, Canada). The primary mouse monoclonal anti-Na<sup>+</sup>,K<sup>+</sup>-ATPase antibody was purchased from AbNova (Cambridge, MA., USA). Cell lysis buffer (10X) and LumiGLO® chemiluminescent substrate were purchased from Cell Signaling Technology (Danvers, MA, USA). The mammalian protease inhibitor cocktail was from Calbiochem (California, USA). The Bradford colorimetric protein assay was purchased from Thermo Fisher Scientific (Waltham, MA, USA), and the Pierce Cell Surface Protein Isolation Kit was purchased from ThermoScientific (Rockford, IL, USA). PK15-NTD (Pig Kidney nucleoside transporter deficient) cells were generously provided by Dr. Ming Tse (Johns Hopkins University, Baltimore, MD, USA). 5'-S-{2-(1-[(fluorescein-5-yl)thioureido]-hexanamido)ethyl}-6-N-(4-nitrobenzyl)-5'-thioadenosine (FTH-SAENTA) was generously donated by Dr. John K. Buolamwini (The University of Tennessee Health Science Centre, Memphis, TN, USA)

### *Site-directed mutagenesis:*

## MOL #79616

Cysteine 297 (Cys297), Cys333, Cys378, Cys414, Cys416, and Cys439 were mutated to serine using the Quikchange mutagenesis kit (Agilent Technologies, Santa Clara, CA) onto the hENT1-p3xFlag template as instructed by the manufacturer. Cys416 and Cys439 were also mutated to alanine for some aspects of the study. All cysteine mutants were transformed into a XL1 Blue strain of *Escherichia coli*, amplified, purified by the Qiagen Miniprep Kit (QIAGEN, Valencia, CA), and sequenced at the London Regional Genomics Centre (London, ON, Canada).

### *Stable Cell Line Generation:*

Cysteine mutants were expressed in the nucleoside transporter deficient cell line (PK15-NTD) as described previously (Park et al., 2011). Briefly, cells were cultured in MEM supplemented with 10% BGS, 100 units of penicillin, 100 µg/ml of streptomycin, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, at 37°C in 5% CO<sub>2</sub> and plated (90% confluent) onto 12-well plates. Cells were transfected with plasmid DNA using Lipofectamine 2000 at a 1:3 ratio (4.8 µl Lipofectamine 2000 and 1.6 µg plasmid DNA). After a 24 hr incubation period, cells were placed under selection for three weeks using G418 at a concentration of 500 µg/ml. Individual colonies surviving the selection period were isolated and grown in the above media supplemented with a lower G418 concentration (300 µg/ml) at 37°C in 5% CO<sub>2</sub>.

### *Transient transfections:*

PK15-NTD cells were transfected with p3xFlag (vector control), hENT1-p3xFlag, and hENT1-cysteine mutants-p3xFlag using Lipofectamine LTX following the manufacturer's instruction (Invitrogen, Burlington, ON, Canada). Briefly, 18.75 µg plasmid DNA was incubated with 3.75 ml Opti-MEM media, 18.75 µl Plus reagent, and 46.87 µl of Lipofectamine LTX for 30 min. The DNA-Lipofectamine complex was then added slowly to near (90%) confluent cells in T75 flasks void of antibiotics and the cells were then incubated at 37°C/5% CO<sub>2</sub> for at least 24 hr prior to harvesting for use in experimental procedures.

### *Cell Membrane Preparations:*



MOL #79616

PK15-NTDs expressing wild-type hENT1 (hENT1-WT) or hENT1-mutants were harvested with 0.05% Trypsin/0.53 mM EDTA, diluted with media containing 10% (v/v) BGS, collected by centrifugation at  $6000 \times g$  and washed twice with PBS and finally suspended in 5 mM sodium phosphate buffer (containing a mammalian protease inhibitor cocktail). Cells were incubated for 30 min on ice to induce cell swelling, and then sonicated using a Sonic Dismembrator model 150 for 30 s and centrifuged at  $3000 \times g$  for 30 min at  $4^{\circ}\text{C}$  to pellet nuclei and unbroken cells. The supernatant containing the crude cell membranes was then centrifuged for 1 hr at  $30000 \times g$  at  $4^{\circ}\text{C}$ . The membrane pellet was suspended in 5 mM sodium phosphate buffer (plus protease inhibitors), and protein content was determined by the Bradford colorimetric assay (Bradford, 1976)

*Treatment with MTS reagents:*

Cells were harvested using 0.05% trypsin/0.53 mM EDTA, diluted with media containing 10% (v/v) BGS, collected by centrifugation at  $6000 \times g$  and washed twice with, and ultimately suspended in, phosphate-buffered saline (PBS; 137 mM NaCl, 6.3 mM  $\text{Na}_2\text{HPO}_4$ , 2.7 mM KCl, 1.5 mM  $\text{KH}_2\text{PO}_4$ , 0.5 mM  $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ , 0.9 mM  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ , pH 7.4,  $22^{\circ}\text{C}$ ) or sodium-free N-methyl-glucamine (NMG) buffer (140 mM NMG, 5 mM KCl, 4.2 mM  $\text{KHCO}_3$ , 0.36 mM  $\text{K}_2\text{HPO}_4$ , 0.44 mM  $\text{KH}_2\text{PO}_4$ , 10 mM HEPES, 0.5 mM  $\text{MgCl}_2$ , and 1.3 mM  $\text{CaCl}_2$ , pH 7.25,  $22^{\circ}\text{C}$ ) for [ $^3\text{H}$ ]NBMPR binding or [ $^3\text{H}$ ]2-chloroadenosine uptake assays, respectively. Cells were treated with 0.1% DMSO (controls) or MTS reagent (1mM MMTS, 5mM MTSET, 5mM MTSES) for 10 min at room temperature We previously showed via a concentration/time course analysis that a 10 min incubation at the MTS concentrations used in this study was sufficient to achieve a maximal effect of each of the reagents on hENT1 activity. (Park et al., 2011). . In some cases, 1 mM adenosine or 10 nM NBMPR were included with the MTS reagent incubation protocol to assess the ability of these ENT1 ligands to protect against MTS reagent modification of the cysteines. After the incubation period, cells were washed ( $6000 \times g$  for 3 min) thrice with PBS or NMG to remove residual MTS reagent and then re-suspended in the appropriate buffer for subsequent experimental analyses.

MOL #79616

*[<sup>3</sup>H]NBMPR binding:*

Cells (~75000 cells/assay) suspended in PBS were incubated with a range of concentrations of [<sup>3</sup>H]NBMPR for 45 min at room temperature (~22°C). Cells were then collected on Whatman Binder-Free Glass Microfiber Filters: Type 934-AH using a 24-port Brandel cell harvester, washed twice with Tris buffer (10 mM, pH 7.4, 4°C) and analyzed for <sup>3</sup>H content using standard liquid scintillation counting techniques. Specific binding was defined as total binding minus cell-associated [<sup>3</sup>H]NBMPR in the presence of 10 μM NBTGR (nonspecific binding).

*FTH-SAENTA Inhibition Assay:*

PK15-NTD cells transfected with hENT1-WT, hENT1-C416A, or hENT1-C439A were incubated with 5 nM [<sup>3</sup>H]NBMPR for 40 min in the presence and absence of 100 nM FTH-SAENTA (membrane-impermeable) or 10 μM NBTGR (membrane-permeable) and then processed as described above for the [<sup>3</sup>H]NBMPR binding assays. FTH-SAENTA would be expected to displace only the [<sup>3</sup>H]NBMPR bound to hENT1 on the plasma membrane as the large fluorescein tag prevents access to intracellular pools (Paproski et al., 2008; Visser et al., 2007).

*[<sup>3</sup>H]2-chloroadenosine uptake:*

Uptake was initiated by the addition of suspended cells (~750000 cells/assay) in NMG buffer to [<sup>3</sup>H]2-chloroadenosine layered over 200 μl of silicon/mineral oil (21:4 vol/vol) in 1.5-ml microcentrifuge tubes. Parallel assays were conducted in the absence (total uptake) and presence (non-mediated uptake) of 5 μM NBMPR/dipyridamole to define the transporter-mediated uptake (total minus non-mediated uptake) of substrate in each cell treatment condition. After a defined incubation time, uptake was terminated by centrifugation for 10 s (~12000 × g). Aqueous substrate and oil layers were removed by aspiration, and pelleted cells were digested in 1 M sodium hydroxide overnight (12–16 hr). A sample of the digest was removed and analyzed for <sup>3</sup>H content using standard liquid scintillation counting techniques. Uptake data

## MOL #79616

are presented as picomoles per microliter of intracellular volume after correction for the amount of extracellular  $^3\text{H}$  in the cell pellet. Total volume was determined by incubating cells with  $^3\text{H}_2\text{O}$  for 3 min and processed as above. Extracellular water space was estimated by extrapolation of the linear time course of non-mediated uptake to zero time.

### *Cell Surface Biotinylation:*

The biotinylation and isolation of cell surface proteins for Western blot analysis was performed as per manufacturer's instructions (Thermo Scientific, Rockford, IL, USA). In brief, PK15-NTD cell monolayers transiently-transfected with hENT1-WT or hENT1-C416A (or un-transfected controls) were washed with cold PBS and incubated for 30 min with membrane impermeable Sulfo-NHS-SS-Biotin on a rocking platform at 4°C. The cells were then harvested and washed with Tris Buffered Saline (TBS) by centrifugation at  $500 \times g$  for 3 min. Cell pellets were lysed, sonicated, and vortex-mixed periodically on ice for 30 min. Cell lysate was centrifuged at  $10000 \times g$  for 2 min at 4°C after which the supernatant was added to a column of NeutrAvidin Agarose and incubated for 60 min at 20°C with end-over-end mixing. The column was then washed extensively with TBS and biotinylated proteins eluted from the column using end-over-end mixing for 60 min with SDS-PAGE sample buffer containing dithiothreitol.

The isolated biotinylated protein samples were loaded into 12% polyacrylamide gels (1.5M Tris pH 8.8, 0.1% sodium dodecyl sulfate, 30% bis-acrylamide, 0.05% ammonium persulfate, 0.05% TEMED) and resolved in the Mini-PROTEAN® Tetra Cell electrophoresis system for ~1 hr at 120V. Following electrophoresis, gels were transferred to polyvinylidene fluoride (PVDF) membranes using a Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell at 440 mA, 20V limit for 45 min. Membranes were blocked for 1 hr at room temperature with 5% skim milk-Tris Buffered Saline Tween buffer (TBST) (0.5 mM Tris, 13.8 mM NaCl, 2.7 mM KCl, 0.05% Tween-20), and then incubated overnight at 4°C with primary monoclonal mouse anti-FLAG antibody (1:2500 in 5% skim milk-TBST). Membranes were washed with TBST and incubated for 1 hr at room temperature with secondary goat anti-mouse HRP conjugated

MOL #79616

antibody (1:25000 in 5% skim milk-TBST), and then washed further with TBST. Membranes were incubated for 1 min with LumiGLO chemiluminescent reagent and then imaged using the Molecular Imager®VersaDoc™ 5000 MP System (Bio-Rad Laboratories, Hercules, CA). Na<sup>+</sup>/K<sup>+</sup>-ATPase was used as a plasma membrane loading control. PVDF membranes were stripped with mild Stripping Buffer (200 mM glycine, 1% Tween-20, and 0.1% sodium dodecyl sulfate; pH 2.2), washed twice with each PBS and TBST before being blocked for 1 hour with 5% skim milk. The PVDF membranes were then incubated overnight at 4°C with primary mouse antibody to Na<sup>+</sup>/K<sup>+</sup>-ATPase (1:2500 in 5% skim milk/TBST). After three washes with TBST, membranes were incubated for 1 hr at room temperature with secondary goat anti-mouse HRP conjugated antibody (1:25000 in 5% skim milk/TBST). After a final three washes, the PVDF membranes were visualized as described above.

*Data analysis and statistics:*

Data are presented as means ± S.E.M. fitted to rectangular (one-site binding/uptake) hyperbolic curves using GraphPad Prism 5 software. Statistical analyses were performed using one-way ANOVA (Dunnett's post-test) or Student's t-test (paired or unpaired), as appropriate, with P < 0.05 considered significant.

MOL #79616

## RESULTS:

We showed previously that a 10 min incubation of intact cells with 1 mM MMTS enhanced the  $B_{\max}$  of [ $^3\text{H}$ ]NBMPR binding and decreased the  $V_{\max}$  of [ $^3\text{H}$ ]2-chloroadenosine uptake, while 5 mM MTSET caused a small but significant decrease in the  $B_{\max}$  of [ $^3\text{H}$ ]NBMPR binding and increased the  $V_{\max}$  of [ $^3\text{H}$ ]2-chloroadenosine uptake (Park et al., 2011). It was also determined that treatment with MMTS, MTSET, or MTSES decreased [ $^3\text{H}$ ]NBMPR binding to hENT1 in broken cell preparations. Similar observations were made for the effects of these MTS reagents on hENT1-WT when tested intermittently throughout the conduct of the present work (Fig. 2A and B).

### *Mutation of Cys297:*

hENT1-C297S transfected cells bound [ $^3\text{H}$ ]NBMPR with a  $K_d$  of  $0.30 \pm 0.04$  nM and transported [ $^3\text{H}$ ]2-chloroadenosine with a  $K_m$  of  $61 \pm 13$   $\mu\text{M}$ , which were not significantly different from the affinities obtained for hENT1-WT (Table 1). The  $B_{\max}$  of [ $^3\text{H}$ ]NBMPR binding and the  $V_{\max}$  of [ $^3\text{H}$ ]2-chloroadenosine uptake by hENT1-C297S cells were  $1.3 \pm 0.3 \times 10^5$  sites per cell and  $5.7 \pm 0.6$  pmol/ $\mu\text{l/s}$ , respectively, giving a translocation rate of  $68 \pm 7$  molecules/ENT1/s. When treated with MMTS, hENT1-C297S showed a  $52 \pm 4\%$  enhancement in the  $B_{\max}$  of [ $^3\text{H}$ ]NBMPR binding with no significant change in  $K_d$ , as seen for the hENT1-WT (Fig. 2C, Table 2). However, MMTS did not affect [ $^3\text{H}$ ]2-chloroadenosine uptake by hENT1-C297S (Fig. 2D, Table 2). Likewise, treatment with MTSET had no effect on [ $^3\text{H}$ ]NBMPR binding to hENT1-C297S, but still led to an increase in the  $V_{\max}$  of [ $^3\text{H}$ ]2-chloroadenosine uptake by these cells. MTSES did not affect [ $^3\text{H}$ ]NBMPR binding or [ $^3\text{H}$ ]2-chloroadenosine uptake by cells transfected with hENT1-C297S (Table 2).

### *Mutation of Cys333:*

## MOL #79616

hENT1-C333S transfected cells bound [<sup>3</sup>H]NBMPR with a  $K_d$  of  $0.37 \pm 0.06$  nM (Table 1) to a maximum of  $4.3 \pm 0.4 \times 10^5$  sites/cell. Transport of [<sup>3</sup>H]2-chloroadenosine by hENT1-C333S had a  $K_m$  and  $V_{max}$  of  $39 \pm 5$   $\mu$ M (Table 1) and  $6.7 \pm 0.7$  pmol/ $\mu$ l/s, respectively indicating that hENT1-C333S had a significantly higher affinity for [<sup>3</sup>H]2-chloroadenosine compared to hENT1-WT. The substrate translocation rate was calculated as  $24 \pm 3$  molecules/ENT1/s which is similar to that determined for hENT1-WT (Park et al., 2011). MMTS treatment led to a  $77 \pm 13\%$  enhancement of the  $B_{max}$  of [<sup>3</sup>H]NBMPR binding to hENT1-C333S (Fig. 2E), similar to that seen for hENT1-WT (Table 2). In contrast, MMTS did not affect [<sup>3</sup>H]2-chloroadenosine uptake by cells transfected with the hENT1-C333S mutant (Fig. 2F, Table 2), nor did MTSES or MTSET have any effect on [<sup>3</sup>H]2-chloroadenosine uptake or [<sup>3</sup>H]NBMPR binding by hENT1-C333S (Table 2).

### *Mutation of Cys378:*

hENT1-C378S transfected cells bound [<sup>3</sup>H]NBMPR with a  $K_d$  of  $0.39 \pm 0.03$  nM (Table 1) to a  $B_{max}$  of  $4.7 \pm 0.4 \times 10^5$  sites/cell. [<sup>3</sup>H]2-chloroadenosine transport by hENT1-C378S had a  $V_{max}$  of  $11 \pm 1$  pmol/ $\mu$ l/s and  $K_m$  of  $57 \pm 6$   $\mu$ M providing a translocation rate of  $35 \pm 3$  molecules/ENT1/s similar to that of hENT1-WT. After treatment with MMTS, the  $B_{max}$  of [<sup>3</sup>H]NBMPR binding to cells transfected with hENT1-C378S increased by  $49 \pm 14\%$  and the  $V_{max}$  of [<sup>3</sup>H]2-chloroadenosine transport decreased by  $40 \pm 12\%$  (Table 2), again similar to that described for the hENT1-WT. However, unlike for hENT1-WT, MTSET and MTSES treatment of this mutant had no effect on either [<sup>3</sup>H]NBMPR binding (Fig. 3A) or [<sup>3</sup>H]2-chloroadenosine transport (Table 2).

### *Mutation of Cys414:*

hENT1-C414S transfected cells bound [<sup>3</sup>H]NBMPR with a  $K_d$  of  $0.45 \pm 0.05$  nM (Table 1) to a maximum of  $2.1 \pm 0.2 \times 10^5$  sites/cell. [<sup>3</sup>H]2-chloroadenosine transport by these cells had a  $V_{max}$  and  $K_m$  of  $6.3 \pm 0.4$  pmol/ $\mu$ l/s and  $35 \pm 5$   $\mu$ M (Table 1), respectively, providing a translocation rate of  $45 \pm 3$  molecules/ENT1/s. Treatment with MMTS increased [<sup>3</sup>H]NBMPR binding  $B_{max}$  by  $98 \pm 12\%$  which was

## MOL #79616

significantly higher than this effect of MMTS on hENT1-WT or any of the other mutants tested (Table 2). MMTS treatment of hENT1-C414S cells also decreased the  $V_{\max}$  of [ $^3\text{H}$ ]2-chloroadenosine transport by  $30 \pm 13\%$  which is similar to that seen for hENT1-WT (Table 2). MTSES did not affect [ $^3\text{H}$ ]NBMPR binding or [ $^3\text{H}$ ]2-chloroadenosine transport by the hENT1-C414S transfected cells (Table 2). MTSET, on the other hand, had a significantly greater inhibitory effect on the binding of [ $^3\text{H}$ ]NBMPR to cells transfected with hENT1-C414S ( $50 \pm 9\%$  decrease in  $B_{\max}$ ) relative to hENT1-WT (Fig. 3B, Table 2).

### *Simultaneous Mutation of Cys378 and Cys414:*

Since mutation of the intracellular Cys414 led to an enhancement of the effect of membrane-impermeable MTSET on the binding of [ $^3\text{H}$ ]NBMPR, and mutation of the predicted extracellular Cys378 eliminated the MTSET sensitivity of hENT1-WT (Fig. 3A, Table 2), and we proposed that the accessibility of Cys378 to MTSET was being influenced by the Cys414 mutation via a conformation change in TM10. To test this hypothesis, Cys378 and Cys414 were both mutated to serine and then tested for MTS reagent sensitivity. Cells transfected with hENT1-C378S/C414S bound [ $^3\text{H}$ ]NBMPR with a  $K_d$  of  $0.22 \pm 0.03$  nM to a  $B_{\max}$  of  $4.6 \pm 0.6 \times 10^{-5}$  sites/cell (Table 1). hENT1-C378S/C414S was able to transport [ $^3\text{H}$ ]2-chloroadenosine with a  $V_{\max}$  and  $K_m$  of  $21 \pm 5$  pmol/ $\mu\text{l/s}$  and  $87 \pm 18$   $\mu\text{M}$  (Table 1), respectively, providing a translocation rate for the double mutant of  $69 \pm 16$  molecules/ENT1/s. After treatment with MMTS, the  $B_{\max}$  of [ $^3\text{H}$ ]NBMPR binding to the hENT1-C378S/C414S transfected cells increased by  $65 \pm 15\%$  and [ $^3\text{H}$ ]2-chloroadenosine transport  $V_{\max}$  showed a large decrease of  $69 \pm 8\%$  (Table 2), similar to hENT1-WT. However, treatment of this mutant with MTSET had no effect on either [ $^3\text{H}$ ]NBMPR binding or [ $^3\text{H}$ ]2-chloroadenosine uptake (Fig. 3C, Table 2), supporting the hypothesis that Cys378 is the target for MTSET effects on hENT1 and that mutation of Cys414 was influencing the accessibility of Cys378 to MTSET.

### *Mutation of Cys416 and Cys439:*

## MOL #79616

Mutation of Cys416 or Cys439 to either serine or alanine led to no [<sup>3</sup>H]2-chloroadenosine transport and no [<sup>3</sup>H]NBMPR binding in stably transfected cells, nor could hENT1 protein be detected by immunoblotting. mRNA for the mutant hENT1 was clearly identified by PCR in these cells (data not shown), so the defect appeared to lie in the production and/or stability of the protein. We speculated initially that the cytoplasmically-located Cys416 could be palmitoylated and thus its removal interfered with proper processing to the plasma membrane. However treatment of hENT1-WT cells with 100 μM 2-Br, a known blocker of palmitoylation, for 24 or 48 hr in serum-free media had no effect on [<sup>3</sup>H]NBMPR binding nor on [<sup>3</sup>H]2-chloroadenosine transport (data not shown).

To circumvent the probability that the inability to stably express these mutants was due to a cellular unfolded-protein response mechanism, we adopted a transient transfection approach. Transient transfection with hENT1-C416A led to the appearance of high-affinity [<sup>3</sup>H]NBMPR binding with a  $K_d$  of  $0.14 \pm 0.02$  and  $B_{max}$  of  $4.6 \pm 2.3 \times 10^5$  sites/cell, similar to that seen for hENT1-WT (Fig. 5A, Table 1). However, these cells did not transport [<sup>3</sup>H]2-chloroadenosine (Fig. 5B). Cell surface biotinylation analysis confirmed that hENT1-C416A was expressed at the plasma membrane (Fig. 6A). Furthermore,  $79 \pm 7\%$  of the specific binding of [<sup>3</sup>H]NBMPR by cells expressing hENT1-C416A could be inhibited by the membrane-impermeable FTH-SAENTA, again indicating that the majority of the hENT1-C416A protein was exposed on the plasma membrane (Fig. 6B). Furthermore, 2-chloroadenosine was able to inhibit the binding of [<sup>3</sup>H]NBMPR to C416A membranes with a  $K_i$  of  $37 \pm 8 \mu\text{M}$ , which is similar to that seen for its inhibition of [<sup>3</sup>H]NBMPR to membranes prepared from cells transfected with hENT1-WT ( $70 \pm 19 \mu\text{M}$ ). Cells transiently transfected with hENT1-C439A bound [<sup>3</sup>H]NBMPR with an affinity ( $K_d$ ) of  $0.47 \pm 0.10$  and a  $B_{max}$  of  $8.6 \pm 1.4 \times 10^5$  sites/cell and, in contrast with C416A, transported [<sup>3</sup>H]2-chloroadenosine with a  $V_{max}$  of  $8.4 \pm 0.8 \text{ pmol}/\mu\text{l}/\text{s}$  and  $K_m$  of  $165 \pm 32 \mu\text{M}$  (Fig. 5, Table 1). The apparent translocation rate of hENT1-C439A was thus  $15 \pm 2$  molecules/ENT1/s which is significantly less than that determined for hENT1-WT ( $38 \pm 3$  molecule/ENT1/s) (Park et al., 2011) and the other mutants tested.



MOL #79616

The effects of the Cys416 and Cys439 mutations on the sensitivity of hENT1 to MTSET and MTSES were then assessed in isolated membranes prepared from cells transiently transfected with hENT1-WT, C416A or C439A . As shown previously (Park et al., 2011), MTSET and MTSES treatment of membranes prepared from hENT1 transfected cells led to a large decrease in the binding of [<sup>3</sup>H]NBMPR (Fig. 7A, Table 3); similar decreases in binding were observed in MTS reagent-treated membranes prepared from C297S, C333S, C378S and C414S stably-transfected cells (data not shown). Likewise, MTSES and MTSET inhibited [<sup>3</sup>H]NBMPR binding to the C439A mutant to a degree similar to that seen for hENT1-WT (Table 3). However, MTSES and MMTS treatment did not decrease [<sup>3</sup>H]NBMPR binding in the C416A mutant (Fig. 7C, Table 3), and the effect of MTSET was attenuated significantly (Fig. 7B) relative to hENT1-WT. The inclusion of NBMPR (10 nM) or the hENT1 substrate adenosine (1 mM) in the MTSES treatment protocol did not affect the ability of MTSES to decrease [<sup>3</sup>H]NBMPR binding (Fig. 8).

MOL #79616

### Discussion:

This study, in conjunction with a previously published study by our laboratory (Park et al., 2011), has identified the cysteine residues responsible for the effects of sulfhydryl reagents on NBMPR binding and hENT1 transporter function. Treatment of intact cells with the positively charged MTSET reagent caused an inhibition in NBMPR binding to hENT1-WT, and mutation of Cys378 to serine abolished this effect. Furthermore, Cys416 appears to be the residue primarily responsible for the inhibitory effects of MTSET and MTSES on [<sup>3</sup>H]NBMPR binding in preparations where the MTS reagents are allowed access to the cytoplasmic side of the protein. The localization of Cys378 at the extracellular interface of TM9 and Cys416 in fifth intracellular loop (IL5), along with the interaction between Cys414 and Cys378, indicates that TM10 and its extracellular and cytoplasmic extensions play an important role in defining the NBMPR binding conformation. We established previously the importance of cysteines located in TM5 and TM6 of hENT1 where Cys222 in TM6 was identified as the residue involved in the enhancement of NBMPR binding by the neutral thiol modifier MMTS, and Cys193 in TM5 was suggested to play a role in the effects of MMTS inhibition of 2-chloroadenosine uptake (Park et al., 2011). It is noteworthy that all of the mutants in that previous study (C87S, C193S, C213S, and C222S) retained high affinity NBMPR binding. Likewise, all mutants in the present study (C297S, C333S, C378S, C414S, C416A, and C439A) bound NBMPR with high affinity (Table 1). These data suggest that none of the cysteines are involved directly in the binding of NBMPR but rather collectively play a role in maintaining the transporter in a conformation compatible with high affinity NBMPR binding.

Mutation of Cys297, Cys333 and Cys378 resulted in the loss of MTSET-mediated inhibition of NBMPR binding, while mutation of the cytoplasmic Cys414 located in IL5 enhanced the ability of MTSET to inhibit the binding of NBMPR. MTSET, as a large membrane-impermeable charged reagent, would not

MOL #79616

gain access to the cytoplasmic Cys414 or likely to the transmembrane region-located Cys297 and Cys333. Thus, it was Cys378, located at the extracellular interface of TM9, that was likely being modified by MTSET. In support of this hypothesis, mutation of Cys378 countered the effect of the Cys414 mutation on MTSET modification of NBMPR binding, with the double mutant being insensitive to MTSET. These results suggested that a mutation in the cytoplasmic portion of the transporter can change the conformation of TM10 leading to enhanced accessibility of the extracellular Cys378 to MTS reagents. A recent study by Yao *et al* also highlighted a role for Cys414 in defining the nucleobase transport capability of hENT1 expressed in a *Xenopus laevis* oocyte model (Yao et al., 2011). It is possible that the conformation change induced in TM10 by the mutation of Cys414 affects the extracellular binding domain for ENT1 substrates and may involve Cys378. . It must also be noted that we have not found any evidence for nucleobase (hypoxanthine) transport by recombinant hENT1 expressed in the PK15-NTD at concentrations of nucleobases below 400  $\mu$ M (unpublished data). Thus, the nucleobase transport observed by hENT1 by Yao *et al* may reflect the expression model used, or higher concentrations of nucleobases than we employed are required to measure observable transporter-mediated uptake.

The present study found that mutation of Cys416 or Cys439 was incompatible with the stable expression of a functional nucleoside transport protein in PK15-NTD cells. However, transient expression of these constructs did result in the expression of hENT1 protein as defined by immunoblotting and NBMPR binding. This suggests that chronic expression of these mutant proteins was deleterious to cell function and were likely degraded via cellular unfolded-protein response mechanisms. Since cysteines can be palmitoylated and this contributes to protein trafficking and membrane tethering (Linder and Deschenes, 2007), we tested the hypothesis that Cys416 and Cys439 were targets for this post-translational modification. Though Cys439 was predicted to be palmitoylated (CSS-Palm 3.0) (Ren et al., 2008) the palmitoylation inhibitor 2-Br had no effect on hENT1 function, suggesting that palmitoylation was not a factor. Additional motifs surrounding the areas of Cys416 and Cys439 include the GxxxG motif known for helix-helix interactions (Polgar et al., 2010; Polgar et al., 2004; Russ and Engelman, 2000) and the

## MOL #79616

endoplasmic reticulum retention signal KKVK (Cosson and Letourneur, 1994; Letourneur et al., 1994). A previous study on PfENT1 has indicated that the GxxxG motif in TM11 is important for folding and/or assembly (Riegelhaupt et al., 2010); we have also found that mutation of Gly445 (of the TM11 GxxxG motif of hENT1) led to a construct that did not result in any protein expression upon stable transfection in PK15-hENT1 cells (Hammond and Cunningham, unpublished). It is noteworthy that mutation of Cys439 (one helix turn N-terminal of the GXXXG motif) to alanine led to a significantly lower  $K_d$  for NBMPR binding and  $K_m$  for 2-chloroadenosine uptake relative to those observed for hENT1-WT and the other cysteine mutants.

A striking finding of this study is that mutation of Cys416 in IL5 to alanine resulted in the transient expression of an hENT1 protein that could bind [ $^3$ H]NBMPR with high affinity, but did not show any [ $^3$ H]2-chloroadenosine transport activity. We considered the possibility that this dissociation between transport and binding may reflect a redistribution of ENT1 proteins to intracellular membranes where they can bind NBMPR (which is membrane permeable) but not contribute to the cellular uptake of nucleosides. However, cell surface biotinylation and FTH-SAENTA competition assays determined that mutation of Cys416 did not change the relative distribution of hENT1 between the plasma membrane and intracellular compartments. Likewise, 2-chloroadenosine was able to inhibit the binding of [ $^3$ H]NBMPR with similar affinity in both the hENT1-WT and hENT1-C416A transfectants. Given that the ability of a substrate to inhibit the binding of [ $^3$ H]NBMPR generally reflects its affinity as an hENT1 substrate, this finding suggests that the loss of [ $^3$ H]2-chloroadenosine transport by hENT1-C416A was not due to a decline in transporter substrate affinity. Therefore, the C416A mutant may be compromised in terms of its substrate translocation mechanism. An *ab initio* structural model of LdNT1.1, a *Leishmania* nucleoside transporter belonging to the ENT family (Valdes et al., 2009) predicts an inner bundle of TM helices (1, 2, 4, 5, 7, 8, 10, 11) encompassing a hydrophilic cavity and the remaining TMs (3, 6, and 9) encircling the inner bundle. Based on that model, our results indicate that the cytoplasmic loop between TM10 and 11 where Cys416 is located may be crucial to maintaining the integrity of the translocation

## MOL #79616

pore. While mutation of Cys416 to an alanine did not affect the binding of [<sup>3</sup>H]NBMPR, modification of this residue with bulky reagents such as MTSES did inhibit binding, giving further credence to the important role of this part of the protein in transporter function. Given that NBMPR is known to bind to the exofacial side of ENT1, and our finding that co-incubation with the ENT1 substrate adenosine or the ENT1 inhibitor NBMPR did not prevent the effects of MTSES on [<sup>3</sup>H]NBMPR binding to cell membranes, it is postulated that modification of Cys416 by the sulfhydryl reagents allosterically disrupts the conformation of the NBMPR binding pocket that is associated with the substrate translocation mechanism.

To conclude, our study has identified Cys378 as an extracellular-located residue modified by MTSET to inhibit the binding of NBMPR. The functional association of Cys378 and Cys414 indicates an allosteric interaction between TM9, TM10 and intracellular loop 5. Conjointly, this study has established Cys416 as the cytoplasmically-located cysteine that is modified by charged sulfhydryl reagents to inhibit the binding of [<sup>3</sup>H]NBMPR. Cys416 may also have a central role in the substrate translocation mechanism of hENT1.

MOL #79616

## ACKNOWLEDGEMENTS

The excellent technical assistance of Diana Quinonez is gratefully acknowledged. We also wish to acknowledge the contribution of Lance Frieberger to this project as part of his undergraduate honors thesis work.

## AUTHORSHIP CONTRIBUTIONS

*Participated in research design:* Hammond, Park

*Conducted experiments:* Park

*Performed data analysis:* Hammond, Park

*Wrote or contributed to the writing of the manuscript:* Hammond, Park

MOL #79616

References:

- Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analytical biochemistry* **72**:248-254.
- Cosson P and Letourneur F (1994) Coatamer interaction with di-lysine endoplasmic reticulum retention motifs. *Science (New York, NY)* **263**(5153):1629-1631.
- Cunha RA (2001) Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. *Neurochemistry international* **38**(2):107-125.
- Dahlig-Harley E, Eilam Y, Paterson AR and Cass CE (1981) Binding of nitrobenzylthioinosine to high-affinity sites on the nucleoside-transport mechanism of HeLa cells. *The Biochemical journal* **200**(2):295-305.
- Endres CJ and Unadkat JD (2005) Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S6-(4-nitrobenzyl)-mercaptapurine riboside, and dipyridamole. *Molecular pharmacology* **67**(3):837-844.
- Jarvis SM and Young JD (1986) Nucleoside transport in rat erythrocytes: two components with differences in sensitivity to inhibition by nitrobenzylthioinosine and p-chloromercuriphenyl sulfonate. *The Journal of membrane biology* **93**(1):1-10.
- King AE, Ackley MA, Cass CE, Young JD and Baldwin SA (2006) Nucleoside transporters: from scavengers to novel therapeutic targets. *Trends in pharmacological sciences* **27**(8):416-425.
- Letourneur F, Gaynor EC, Hennecke S, Demolliere C, Duden R, Emr SD, Riezman H and Cosson P (1994) Coatamer is essential for retrieval of dilysine-tagged proteins to the endoplasmic reticulum. *Cell* **79**(7):1199-1207.
- Linder ME and Deschenes RJ (2007) Palmitoylation: policing protein stability and traffic. *Nature reviews* **8**(1):74-84.
- Loffler M, Morote-Garcia JC, Eltzschig SA, Coe IR and Eltzschig HK (2007) Physiological roles of vascular nucleoside transporters. *Arteriosclerosis, thrombosis, and vascular biology* **27**(5):1004-1013.
- Paproski RJ, Ng AM, Yao SY, Graham K, Young JD and Cass CE (2008) The role of human nucleoside transporters in uptake of 3'-deoxy-3'-fluorothymidine. *Molecular pharmacology* **74**(5):1372-1380.
- Park JS, Hughes SJ, Cunningham FK and Hammond JR (2011) Identification of cysteines involved in the effects of methanethiosulfonate reagents on human equilibrative nucleoside transporter 1. *Molecular pharmacology* **80**(4):735-746.
- Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larrayoz I, Martinez-Picado J and Casado FJ (2005) Cell entry and export of nucleoside analogues. *Virus Res* **107**(2):151-164.
- Polgar O, Ierano C, Tamaki A, Stanley B, Ward Y, Xia D, Tarasova N, Robey RW and Bates SE (2010) Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2. *Biochemistry* **49**(10):2235-2245.

MOL #79616

- Polgar O, Robey RW, Morisaki K, Dean M, Michejda C, Sauna ZE, Ambudkar SV, Tarasova N and Bates SE (2004) Mutational analysis of ABCG2: role of the GXXXG motif. *Biochemistry* **43**(29):9448-9456.
- Ren J, Wen L, Gao X, Jin C, Xue Y and Yao X (2008) CSS-Palm 2.0: an updated software for palmitoylation sites prediction. *Protein Eng Des Sel* **21**(11):639-644.
- Riegelhaupt PM, Frame IJ and Akabas MH (2010) Transmembrane segment 11 appears to line the purine permeation pathway of the Plasmodium falciparum equilibrative nucleoside transporter 1 (PfENT1). *The Journal of biological chemistry* **285**(22):17001-17010.
- Robillard KR, Bone DB, Park JS and Hammond JR (2008) Characterization of mENT1Delta11, a novel alternative splice variant of the mouse equilibrative nucleoside transporter 1. *Molecular pharmacology* **74**(1):264-273.
- Russ WP and Engelman DM (2000) The GxxxG motif: a framework for transmembrane helix-helix association. *Journal of molecular biology* **296**(3):911-919.
- SenGupta DJ, Lum PY, Lai Y, Shubochkina E, Bakken AH, Schneider G and Unadkat JD (2002) A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine. *Biochemistry* **41**(5):1512-1519.
- SenGupta DJ and Unadkat JD (2004) Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep. *Biochemical pharmacology* **67**(3):453-458.
- Sundaram M, Yao SY, Ingram JC, Berry ZA, Abidi F, Cass CE, Baldwin SA and Young JD (2001a) Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anticancer drugs. *The Journal of biological chemistry* **276**(48):45270-45275.
- Sundaram M, Yao SY, Ng AM, Cass CE, Baldwin SA and Young JD (2001b) Equilibrative nucleoside transporters: mapping regions of interaction for the substrate analogue nitrobenzylthioinosine (NBMPR) using rat chimeric proteins. *Biochemistry* **40**(27):8146-8151.
- Sundaram M, Yao SY, Ng AM, Griffiths M, Cass CE, Baldwin SA and Young JD (1998) Chimeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs. *The Journal of biological chemistry* **273**(34):21519-21525.
- Valdes R, Arastu-Kapur S, Landfear SM and Shinde U (2009) An ab Initio structural model of a nucleoside permease predicts functionally important residues. *The Journal of biological chemistry* **284**(28):19067-19076.
- Valdes R, Vasudevan G, Conklin D and Landfear SM (2004) Transmembrane domain 5 of the LdNT1.1 nucleoside transporter is an amphipathic helix that forms part of the nucleoside translocation pathway. *Biochemistry* **43**(21):6793-6802.
- Visser F, Baldwin SA, Isaac RE, Young JD and Cass CE (2005) Identification and mutational analysis of amino acid residues involved in dipyridamole interactions with human and *Caenorhabditis elegans* equilibrative nucleoside transporters. *The Journal of biological chemistry* **280**(12):11025-11034.
- Visser F, Sun L, Damaraju V, Tackaberry T, Peng Y, Robins MJ, Baldwin SA, Young JD and Cass CE (2007) Residues 334 and 338 in transmembrane segment 8 of human equilibrative nucleoside transporter 1 are important determinants of inhibitor sensitivity,



MOL #79616

- protein folding, and catalytic turnover. *The Journal of biological chemistry* **282**(19):14148-14157.
- Vyas S, Ahmadi B and Hammond JR (2002) Complex effects of sulfhydryl reagents on ligand interactions with nucleoside transporters: evidence for multiple populations of ENT1 transporters with differential sensitivities to N-ethylmaleimide. *Archives of biochemistry and biophysics* **403**(1):92-102.
- Yao SY, Ng AM, Cass CE, Baldwin SA and Young JD (2011) Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). *The Journal of biological chemistry* **286**(37):32552-32562.
- Zhang J, Visser F, King KM, Baldwin SA, Young JD and Cass CE (2007) The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. *Cancer metastasis reviews* **26**(1):85-110.

MOL #79616

## FOOTNOTES

This work was supported by a grant (to J.R.H.) and a postgraduate scholarship (to J.S.P) from the Natural Sciences and Engineering Research Council of Canada. Support for the graduate training of J.S.P. was also provided by the Schulich School of Medicine and Dentistry, Western University.

Reprint requests to be sent to: Dr James R Hammond, Dept. of Physiology and Pharmacology, M266 Medical Sciences Building, Western University, London, Ontario, N6A 5C1, Canada.

MOL #79616

## FIG. LEGENDS

**Fig. 1. Predicted transmembrane topology of hENT1 with locations of the ten cysteine residues indicated.** The cysteines targeted in the present study were Cys297, Cys333, Cys378, Cys414, Cys416 and Cys439 in the C-terminal half of the protein.

**Fig. 2. Effects of MMTS on [<sup>3</sup>H]NBMPR binding and [<sup>3</sup>H]2-chloroadenosine uptake by hENT1-WT, hENT1-C297S and hENT1-C333S expressed in PK15-NTD cells.** Cells were incubated with either 1 mM MMTS or 0.1% DMSO (Control) for 10 min and then washed thrice before use in the following assays. **Panels A,C,E:** Cells were incubated with a range of concentrations of [<sup>3</sup>H]NBMPR (abscissa) in the presence and absence of 10 μM NBTGR to define total and nonspecific binding. Specific binding (ordinate) was calculated as the difference between the total and nonspecific binding components. Each point represents the mean ± S.E.M. from at least five experiments done in duplicate. **Panels B,D,F:** Cells were incubated with a range of concentrations of [<sup>3</sup>H]2-chloroadenosine (abscissa) for 5 s in the presence (non-mediated) or absence (total uptake) of 5 μM dipyridamole/NBTGR. Transporter-mediated uptake (ordinate) was calculated as the difference between the total and non-mediated uptake components. Each point represents the mean ± S.E.M. of the cellular accumulation of [<sup>3</sup>H]2-chloroadenosine from at least four independent experiments conducted in duplicate. The hENT1-WT cells were assessed in parallel with the hENT1-C297S transfected cells.

**Fig. 3. Effects of MTSET on [<sup>3</sup>H]NBMPR binding by hENT1-WT (Panel A) hENT1-C378S (Panel B), hENT1-C414S (Panel C), and C378-414S-hENT1 (Panel D) expressed in PK15-NTD cells.** Cells were incubated with either 5 mM MTSET or 0.5% DMSO (Control) for 10 min, washed extensively, and then incubated with a range of concentrations of [<sup>3</sup>H]NBMPR in the presence and absence of 10 μM NBTGR to define total and nonspecific binding, respectively. Specific binding was calculated as the

MOL #79616

difference between the total and nonspecific binding components. Each point represents the mean  $\pm$  S.E.M. from at least five experiments done in duplicate.

**Fig. 4. Effect of palmitoylation inhibition on [<sup>3</sup>H]NBMPR binding and [<sup>3</sup>H]2-chloroadenosine uptake by hENT1 expressed in PK15-NTD cells.** Cells transfected with hENT1-WT were treated with the palmitoylation inhibitor 2-Br (100  $\mu$ M) or DMSO (Control) for 24 or 48 hr in serum-free media. Cells were harvested, washed, and subjected to either [<sup>3</sup>H]NBMPR binding (Panel A) or [<sup>3</sup>H]2-chloroadenosine uptake (Panel B) assays. Each point represents the mean  $\pm$  S.E.M. from at least four independent experiments conducted in duplicate.

**Fig. 5. [<sup>3</sup>H]NBMPR binding and [<sup>3</sup>H]2-chloroadenosine uptake by PK15-NTD cells transfected with hENT1-C416A or hENT1-C439A. Panel A.** Cells were incubated with a range of concentrations of [<sup>3</sup>H]NBMPR in the absence (total binding) and presence (nonspecific binding) of 10  $\mu$ M NBTGR. Specific binding was calculated as the difference between the total and nonspecific binding components. Each point represents the mean  $\pm$  S.E.M. from at least five experiments done in duplicate. **Panel B.** Cells were incubated with a range of concentrations of [<sup>3</sup>H]2-chloroadenosine for 5 s in the presence (non-mediated) or absence (total uptake) of 5  $\mu$ M dipyridamole/NBTGR. Transporter-mediated uptake was calculated as the difference between the total and non-mediated uptake components. Each point represents the mean  $\pm$  S.E.M. of the cellular accumulation of [<sup>3</sup>H]2-chloroadenosine from at least four independent experiments conducted in duplicate.

**Fig. 6. Analysis of the plasma membrane expression of hENT1 via biotinylation and FTH-SAENTA competition assays. Panel A.** Un-transfected PK15-NTD or cells transiently-transfected with hENT1-WT or hENT1-C416A were cell-surface biotinylated and isolated via avidin-linked agarose columns as described in Materials and Methods. Recombinant hENT1-WT and hENT1-C416A were visualized with mouse anti-FLAG antibodies (1:2500), and blots were then stripped and probed with anti-Na<sup>+</sup>/K<sup>+</sup>-ATPase

MOL #79616

antibody (1:2500) to assess plasma membrane loading levels. **Panel B.** Cells transfected with hENT1-WT, C416A, or C439A were incubated with 5 nM [<sup>3</sup>H]NBMPR for 45 min in the absence or presence of either 100 nM FTH-SAENTA or 10 μM NBTGR. The total number of ENT1-associated NBMPR binding sites (specific binding) was calculated as the total binding of [<sup>3</sup>H]NBMPR (absence of inhibitors) minus non-specific binding (in presence of the membrane-permeable 10 μM NBTGR). Cell surface binding was calculated as the difference in specific binding with and without co-incubation with the membrane-impermeable inhibitor FTH-SAENTA. Data are shown as the ratio of cell surface binding to total ENT1-associated binding of [<sup>3</sup>H]NBMPR. Each bar represents the mean ± S.E.M. of three independent experiments.

**Fig. 7. Effect of MTS reagents on [<sup>3</sup>H]NBMPR binding by PK15-NTD cells transiently transfected with hENT1-WT or hENT1-C416A.** Membranes prepared from hENT1-WT or hENT1-C416A were incubated for 10 min in the absence or presence of 1 mM MMTS, 5 mM MTSET, or 5 mM MTSES for 10 min at room temperature, washed extensively, and then incubated with a range of concentrations of [<sup>3</sup>H]NBMPR in the presence and absence of 10 μM NBTGR to define total and nonspecific binding. **Panel A and Panel B** describes the binding profile ± MTSET in hENT1-WT and hENT1-C416A transfected cells, respectively. Each point represents the mean ± S.E.M. from at least five experiments done in duplicate. **Panel C** shows the results obtained as described for Panels A and B for each of the MTS reagents with data presented as the percent change in specific binding ± S.E.M. upon treatment with each sulfhydryl modifier. Data for MTSES and MMTS are from three experiments conducted in duplicate. \* Indicates a significant effect of the MTS reagent (Student's t-test, p < 0.05)

**Fig. 8. NBMPR and adenosine are unable to protect against MTSES-induced inhibition of [<sup>3</sup>H]NBMPR binding in cell membranes.** Membranes isolated from PK15-NTD cells transfected with hENT1-WT were incubated for 10 min at room temperature with 0.5% DMSO (control) or 5 mM MTSES in the absence and presence of 10 nM NBMPR (**Panel A**) or 1 mM adenosine (**Panel B**). After extensive

MOL #79616

washing to remove NBMPR/adenosine and un-reacted MTSES, membranes were exposed to a range of concentrations of [<sup>3</sup>H]NBMPR in the presence and absence of 10 μM NBTGR to define the site-specific binding. Each point is the mean ± S.E.M. from at least four experiments conducted in duplicate.

MOL #79616

**Table 1. Affinity of [<sup>3</sup>H]NBMPR and [<sup>3</sup>H]2-chloroadenosine for binding and uptake, respectively, by hENT1 cysteine mutants expressed in PK15-NTD cells.** Data shown are the means ± S.E.M. from at least three independent experiments conducted as described in Figs. 2-6.

Cell Line	[ <sup>3</sup> H]NBMPR	[ <sup>3</sup> H]2-Chloroadenosine
	Binding Kd (nM)	Uptake Km (μM)
hENT1-WT <sup>#</sup>	0.38 ±0.02	71±8
C297S	0.30±0.04	62±13
C333S	0.37±0.06	40±5.4*
C378S	0.39±0.03	58±6.2
C414S	0.45±0.05	35±5.0*
C378S/C414S	0.22 ± 0.03*	87 ± 18
C416A	0.14± 0.02*	nd
C439A	0.47±0.10	165±31*

\* Significant difference compared to hENT1-WT (Student's *t* test for paired samples, *P* <0.05). nd = not detected

<sup>#</sup> from Park, J.S. *et al.* (2011)

MOL #79616

**Table 2. Effects of MTS reagents on [<sup>3</sup>H]NBMPR binding (B<sub>max</sub>) and [<sup>3</sup>H]2-chloroadenosine uptake (V<sub>max</sub>) by cells transfected with hENT1 cysteine mutants.**

Data shown are the means ± S.E.M. from at least three independent experiments conducted as described in Figs. 2-5.

Cell Line	MTS Reagent	[ <sup>3</sup> H]NBMPR Binding		[ <sup>3</sup> H]2-Chloroadenosine Uptake	
		Control	Treated	Control	Treated
			<b>B<sub>max</sub> (sites/cell X 10<sup>5</sup>)</b>		<b>V<sub>max</sub> (pmol/μl/s)</b>
hENT1-WT #	MMTS	3.9 ± 0.4	<b>5.6 ± 0.4*</b>	10.8 ± 1.1	<b>6.4 ± 1.0*</b>
	MTSET	3.6 ± 0.4	<b>3.2 ± 0.3*</b>	9.1 ± 1.6	<b>11.3 ± 1.7*</b>
	MTSES	4.1 ± 0.5	4.0 ± 0.7	8.1 ± 1.2	7.6 ± 1.1
C297S	MMTS	1.2 ± 0.2	<b>1.9 ± 0.3*</b>	6.8 ± 0.8	6.6 ± 0.03
	MTSET	1.7 ± 0.4	1.3 ± 0.2	5.1 ± 1.6	<b>8.1 ± 1.8*</b>
	MTSES	1.0 ± 0.2	0.9 ± 0.1	6.5 ± 1.7	6.2 ± 0.2
C333S	MMTS	4.3 ± 0.5	<b>7.7 ± 1.5*</b>	7.8 ± 1.6	9.8 ± 2.4
	MTSET	3.5 ± 0.4	3.0 ± 0.8	5.8 ± 1.2	5.7 ± 0.8
	MTSES	5.0 ± 1.1	4.6 ± 1.4	6.2 ± 0.2	6.8 ± 0.9
C378S	MMTS	5.1 ± 0.7	<b>7.6 ± 1.2*</b>	17 ± 2.9	<b>9.8 ± 1.3*</b>
	MTSET	4.5 ± 0.5	4.3 ± 0.8	12 ± 1.5	12 ± 1.2
	MTSES	4.5 ± 0.6	4.2 ± 0.7	3.7 ± 0.6	3.2 ± 1.2
C414S	MMTS	1.5 ± 0.3	<b>3.1 ± 0.4*</b>	6.7 ± 0.9	<b>4.6 ± 0.7*</b>
	MTSET	2.0 ± 0.3	<b>1.1 ± 0.2*</b>	6.6 ± 0.7	5.8 ± 0.5
	MTSES	2.4 ± 0.4	2.4 ± 0.4	5.1 ± 0.2	5.7 ± 0.6
C378S/C414S	MMTS	6.1 ± 0.3	<b>10 ± 0.8*</b>	25 ± 4.2	<b>7.8 ± 1.3*</b>
	MTSET	3.2 ± 0.3	3.0 ± 0.3	24 ± 10	29 ± 18
	MTSES	5.6 ± 2.0	5.8 ± 2.0	15 ± 3.6	13 ± 2.5

\* Significant difference from control (Student's *t* test for paired samples, *P* < 0.05)

# from Park, J.S. *et al.* (2011)



MOL #79616


**Table 3. Effects of MTS reagents on [<sup>3</sup>H]NBMPR binding to membranes prepared from cells transfected with hENT1-WT, C416A, or C439A.** Membranes were prepared from cells 24 hr following transfection with the indicated hENT1 construct. The isolated membranes were then assessed for their level of site-specific [<sup>3</sup>H]NBMPR binding as described for Fig. 7.

Values shown are the means ± S.E.M. from at least three independent experiments conducted in duplicate.


		<b>[<sup>3</sup>H]NBMPR Binding</b>	
		<b>B<sub>max</sub> (pmol/mg)</b>	
Cell Line	MTS Reagent	Control	Treated
hENT1-WT	MMTS	1.24 ± 0.34	1.03 ± 0.17
	MTSET	3.15 ± 0.94	<b>0.78 ± 0.28*</b>
	MTSES	3.19 ± 1.51	<b>1.92 ± 0.85*</b>
C416A	MMTS	1.23 ± 0.19	1.42 ± 0.29
	MTSET	2.73 ± 1.17	2.30 ± 1.14
	MTSES	2.33 ± 0.97	2.34 ± 0.97
C439A	MMTS	0.99 ± 0.23	0.78 ± 0.08
	MTSET	4.29 ± 1.78	<b>1.13 ± 0.42*</b>
	MTSES	1.57 ± 0.61	<b>0.71 ± 0.25*</b>

\* Significant difference from control (Student's *t* test for paired samples, *P* < 0.05)


FIGURE 1




# FIGURE 2



# FIGURE 3




**FIGURE 4**




# FIGURE 5

## A. NBMPR Binding




## B. 2-Chloroadenosine Uptake




# FIGURE 6

A.




B.




# FIGURE 7


## A. hENT1- WT Membranes



## B. hENT1- C416A Membranes



## C.





**FIGURE 8**

